DelSiTech Ltd Receives Significant Funding from the Bill & Melinda Gates Foundation for Developing Long-Acting Injectables

TURKU, FinlandMay 21, 2019 /PRNewswire/ — DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced significant grant funding to support the development of long-acting controlled release formulations for family planning as well as for human immunodeficiency virus (HIV) antivirals, from the Bill & Melinda Gates Foundation.

DelSiTech is the global leader in advanced silica-based, sustained and controlled release delivery technologies for administration of injectable, implant and topical eye drop dosage forms. Its technology offers long-acting injectable medical solutions to enable longer treatment periods and fewer injections.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...